Skip to content

When side effects threaten continuityiDose TR shows a strong, uncompromising safety profile1

Through 36 months2,3,*:

Stylized zero character

Zero clinically significant endothelial cell loss

  • Zero periorbital fat atrophy
  • Zero serious corneal AEs
  • Zero DSAEK
  • Zero DMEK

Implant designed to
remain fixed and stable

Positioned parallel to the iris, away from the corneal endothelium1

Most adverse reactions were mild or moderate and resolved1

The most commonly reported ocular adverse reactions (2%-6%)

Phase 2b and Phase 3 Trials Combined Through 12 months | N=868

  • Increases in intraocular pressure
  • Eye pain
  • Iritis
  • Ocular hyperemia
  • Dry eye
  • Reduced visual acuity
  • Visual field defects

Includes both slow-eluting and fast-eluting implants. The slow-eluting implant is the only approved and commercially marketed version.2

iDOSE TR EFFICACY

GLAUKOS SUPPORT

Ready to hear more?

Contact a representative to request more info.

*Inclusive of Phase 3 and Phase 2b trials.
AE=adverse event; DSAEK=Descemet’s stripping automated endothelial keratoplasty; DMEK=Descemet’s membrane endothelial keratoplasty.

References: 1. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023. 2. Berdahl JP, Sarkisian SR Jr, Ang RE, et al. Efficacy and safety of the travoprost intraocular implant in reducing topical IOP‐lowering medication burden in patients with open‐angle glaucoma or ocular hypertension. Drugs. 2024;84(1):83-97. 3. Data on file, Glaukos Corporation.

Important Safety Information

Dosage and Administration

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

Contraindications

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings and Precautions

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Indications and Usage

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Please see full Prescribing Information.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

The information contained in this site is intended for US healthcare professionals only.

YES, I AM A US HEALTHCARE PROFESSIONAL NO, I AM NOT A US HEALTHCARE PROFESSIONAL

Request more info

"*" indicates required fields

*Required.

By entering this information, you confirm that you are at least 18 years old and that you have read and accept the terms of our Privacy Policy. Glaukos will use the information you provide on this form to provide product updates and other promotional materials. Should you change your mind, you may unsubscribe using the link in the footer of any email you receive from us.

Stay connected

Sign up to receive the latest information about iDose® TR!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
*Required.

Glaukos will use the information you provide on this form to get in touch with you.

By entering this information, you confirm that you are at least 18 years old and that you have read and accept the terms of our Privacy Policy. Glaukos will use the information you provide on this form to provide product updates and other promotional materials. Should you change your mind, you may unsubscribe using the link in the footer of any email you receive from us.